1	
2	
3	
	Causal Effects of Harpoovirus Accosisted Antibadias on
4	Causal Enects of herpesvirus-Associated Antibodies of
5	Autoimmune neuroinflammatory diseases: Mendelian
6	Randomization Study
7	
8	Shujun Sun <sup>1¶</sup> , Yiyong Wen <sup>2¶</sup> , Pan tang², Fan xie², Jun wen², Anding Xu³*
9	1. Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan
10	University;
11	Guangzhou, Guangdong 510632, China.
12	
13	2.Department of Neurology, Changde Hospital, Xiangya School of Medicine, Central
14	South University (The first people's hospital of Changde city)
15	No. 388 Renmin East Road, Changde City, Hunan Province, China.
16	
17	3.:Department of Neurology and Stroke Center,
18	Key Lab of Guangzhou Basic and Translational Research of Pan-vascular Diseases
19	The First Affiliated Hospital of Jinan University
20	Guangzhou, Guangdong 510632, China
21 N	IOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 22 \* Corresponding author

23 E-mail: tlil@jnu.edu.cn.

24

25 † Shujun Sun and Yiyong Wen have contributed equally to this work.

26

## 27 Abstract

28 Background: Herpesvirus infections may trigger Autoimmune neuroinflammatory 29 diseases (ANDs), but their causal role is uncertain. This study used Mendelian 30 randomization (MR) to investigate the causal effects of herpesvirus antibodies on ANDs. Methods: We assessed 22 herpesvirus antibodies and five ANDs-multiple sclerosis 31 32 (MS), neuromyelitis optica (NMO), myasthenia gravis (MG), Guillain-Barr é syndrome 33 (GBS), and chronic inflammatory demyelinating polyneuropathy (CIDP)-using five MR 34 methods. MR-PRESSO, MR-Egger, and Cochran's Q statistic identified pleiotropy and 35 heterogeneity. Bonferroni correction set the significance threshold at P<4.545e-04. 36 Validation used UK Biobank and FinnGen data, with meta-analysis for inconsistent 37 results. Results: Significant positive causal effects were found for Epstein-Barr virus encoded nuclear antigen-1 (EBV EBNA-1) (OR=3.009), EBV viral capsid antigen (VCA) 38 39 p18 (OR=8.700), and human herpesvirus 7(HHV7) U14 (OR=3.359) antibody levels 40 on MS risk, and HHV7 U14 (OR=10.641), Varicella zoster virus glycoprotein E and 41 glycoprotein I(VZV gE and gI) (OR=17.220) antibody levels on NMO risk. VZV gE and gI 42 (OR=2.542) antibodies increased MG risk, while EBV ZEBRA (OR=0.592) reduced 43 MS risk. Negative effects of EBV EA-D and ZEBRA antibodies on NMO were also noted.

Validation confirmed the effects of EBV EBNA-1, EBV VCA p18 antibodies on MS, and
VZV gE and gI on antibody MG, while EBV ZEBRA and HHV7 U14 antibodies effects on
MS were not validated. Conclusions: The study suggests a causal link between specific
herpesvirus antibodies and the risk of MS, NMO, and MG.

Kewords: Autoimmune neuroinflammatory diseases, multiple sclerosis, neuromyelitis
 optica, myasthenia gravis, Epstein-Barr virus, human herpesvirus, varicella zoster virus,
 antibody

52

## 53 Introduction

54 Autoimmune neuroinflammatory diseases (ANDs) are a category of disorders in 55 which the immune system mistakenly targets and attacks the nervous system, resulting 56 in inevitable structural and functional damage[1, 2]. Autoimmune neurological diseases 57 (ANDs) include mainly multiple sclerosis (MS), neuromyelitis optica (NMO), Guillain-Barr 58 é syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and 59 myasthenia gravis (MG). MS and NMO affect the central nervous system (CNS), GBS 60 and CIDP affect the peripheral nervous system (PNS), and MG affects the 61 neuromuscular junction (NMJ). These conditions lead to neuronal or axonal damage, 62 demyelination, damage to the nerve-muscle junction and other pathological changes [3, 63 4].

64 The incidence and prevalence of autoimmune diseases are increasing worldwide 65 every year, but the exact causes of these diseases remain unknown; however, it is

66 thought that a mixture of genetic and environmental factors play a role in their 67 development [5]. Infections seem to be a common trigger for autoimmune diseases [6].

68 Several viruses of the Herpesviridae family have been implicated as an important 69 risk factor for ANDs, Epstein-Barr virus (EBV) has been implicated as a major cause of 70 multiple sclerosis [7], the risk of MS increases 32-fold following infection with EBV [8]. 71 Human herpesvirus 6A (HHV-6A) has been associated with a higher risk of developing 72 multiple sclerosis. Cytomegalovirus (CMV) infection may be associated with the 73 occurrence of aquaporin-4 antibody-positive NMO spectrum disorder (AQP4 IgG+ 74 NMOSD) [9]. CMV and EBV are also frequently identified as antecedent pathogens of 75 GBS [10]. Case reports of CIDP have found associations with CMV and EBV [11].

The association between EBV infection and the pathogenesis of MG remains controversial [12, 13]. Meanwhile, the associations between viruses of the Herpesviridae family and MG remain unclear. Existing observational studies and case reports have limited sample sizes, which reduces the statistical power to detect true associations and increases the likelihood of random error. In addition, it is difficult to draw causal conclusions from observational evidence due to residual confounding and reverse causation [14].

Mendelian randomisation (MR) is a novel approach that may offer more effective solutions to the above shortcomings. MR uses genetic variations that affect exposure as instrumental variables (IVs) to assess the causal relationship between exposure and outcomes. Because alleles are randomly assigned at conception, they are unaffected by confounding factors and disease states. By using genetic variants as IVs, MR can reduce

the confounding effects of environmental factors and avoid reverse causation bias [15,16].

90 Previous MR studies have found no association between herpes simplex virus (HSV) 91 infection and MS [17], whereas varicella infection is associated with MS [18]. Compared 92 to viral infections, antibody immune responses may not only serve as markers of infection 93 exposure, but also potentially provide clues to the pathophysiological mechanisms 94 associated with ANDs. However, whether there is a causal relationship between these 95 common herpesvirus-induced antibody immune responses and ANDs is unknown, and to 96 the best of our knowledge, our study will be the first to investigate the causal relationship between herpesvirus antibodies and ANDs, thereby further exploring new potential 97 98 therapeutic targets and potentially informing vaccine selection for patients with ANDs.

## 99 Materials and Methods

## 100 Study Design

101 MR analysis is a statistical technique used to identify causal relationships, 102 particularly within observational data. It uses genetic variants that influence exposure as 103 instrumental variables (IVs) to assess the causal relationship between exposure and 104 outcomes. A key advantage of MR analysis is its ability to mitigate bias arising from 105 confounding and reverse causation, as genetic variations are generally not influenced by 106 environmental or behavioural factors [15, 16]. MR studies will help to overcome current 107 obstacles in investigating the relationship between antibody immune responses following 108 herpesvirus infection and various ANDs, thus facilitating a more accurate investigation of 109 direct causal relationships.

## 110 Data Source

111 Our study investigated the immune response of 22 antibodies to five types of herpesvirus infection: Anti-CMV IgG seropositivity, CMV pp28 antibody levels, CMV pp52 112 113 antibody levels, CMV pp150 antibody levels; Anti-EBV IgG seropositivity, EBV early antigen-D (EA-D) antibody levels, EBV encoded nuclear antigen-1 (EBNA-1) antibody 114 115 levels, EBV viral capsid antigen (VCA) p18 antibody levels, EBV ZEBRA antibody levels; 116 Anti-HHV6 IgG seropositivity, Anti-HHV6 IE1A IgG seropositivity, HHV6 IE1A antibody level, Anti-HHV6 IE1B IgG seropositivity, HHV6 IE1B antibody level, HHV6 p101k 117 118 antibody level, Anti-HHV7 IgG seropositivity, HHV7 U14 antibody levels, Anti-HSV1 IgG 119 seropositivity, HSV1 mgG-1 antibody levels, Anti-HSV2 lgG seropositivity, HSV2 mgG-1 120 antibody levels; Varicella zoster virus glycoprotein E and I (VZV gE and gI) antibody 121 levels.

122 The above immune responses were investigated in a Genome-Wide Association 123 Study (GWAS) involving a total of 8,735 individuals for case-control phenotypes and an 124 average (range) of 4,286 (276-8,555) samples per guantitative analysis [19].

Genome-wide summary data for MS consisting of 47,429 cases and 68,374 controls from the European population were obtained from the International MS Genetics Consortium (IMSGC) [20]. To further validate the positive results, UK Biobank (1679 cases and 461254 controls, https://gwas.mrcieu.ac.uk/datasets/ukb-b-17670/) and FinnGen (2620 cases and 449770 controls, https://r11.finngen.fi/pheno/G6\_MS) for MS were used.

131 NMO-related GWAS data were obtained from the largest and most recent NMO

132 GWAS meta-analysis, which included 215 NMO cases and 1,244 controls [21].

133	The largest MG GWAS reported by Chia et al. was used for the primary analysis in
134	this study, which included 1,873 cases and 36,370 controls [22]
135	(https://www.ebi.ac.uk/gwas/).The MG GWAS focused only on cases positive for anti-
136	acetylcholine receptor antibodies (anti-AChR), excluding individuals positive for
137	antibodies to muscle-specific kinase (anti-MuSK). For external validation, summary
138	statistics were obtained from the UK Biobank (224 cases and 417332 controls,
139	http://www.nealelab.is/uk-biobank) and the FinnGen (504 cases and 449570 controls,
140	https://r11.finngen.fi/pheno/G6_MYASTHENIA).

For GBS, data were obtained from the FinnGen Biobank with 489 cases and 445865 controls (https://r11.finngen.fi/pheno/G6\_GUILBAR). Genetic associations for CIDP were derived from 456,348 individuals of European ancestry from the UK Biobank using a fast genome-wide association generalised linear mixed model and were obtained from the catalogue [23]. Detailed information of Data used in our study was shown in supplementary table 1.

## 147 Instrumental Variable Selection

We screened single nucleotide polymorphisms (SNPs) that showed a significant association with exposure factors in the exposure GWAS ( $P < 5 \times 10-8$ ).When the number of SNPs was less than 10, we relaxed the SNPs selection criterion to a p-value threshold of p<1e-07 or p<1e-06, with a minimum standard of p<1e-05 [24]. SNPs with minor allele frequencies (MAF < 0.01) were also deleted, and linkage disequilibrium (LD) between SNPs was resolved by clustering (R2<0.001 within a 10 Mkb clustering

154	distance). Palindromic SNPs were removed. The exposure and outcome data sets were
155	then harmonised. The proportion of variance explained by instrumental variables was
156	calculated using the formula: R2 = 2 × $\beta$ 2 × EAF × (1 - EAF)/(2 × $\beta$ 2 × EAF × (1 - EAF) +
157	2 × SE2 × N × EAF × (1 - EAF)), where N is the sample size [25]. The power of the
158	genetic instrument was assessed using the F-statistic, calculated as F= R2 $\times$ (N - 2)/(1 -
159	R2). An F-statistic greater than 10 indicates a strong instrument, IVs with F-statistics less
160	than 10 were considered weak and thus excluded from the analysis. The
161	SNiPA(https://snipa.org/snipa3/) and GWAS catalogue(https://www.ebi.ac.uk/gwas/home)
162	was used to check that the SNPs were not associated with other relevant confounders,
163	such as smoking, body mass index (BMI), physical activity, serum 25-hydroxyvitamin D
164	levels.

## 165 Mendelian Randomization Analysis

When there was only one IV, the Wald ratio method was utilized. In cases where two IVs were present, Inverse Variance Weighted (IVW) method will be used. With more than two instrumental variables (IVs) available, univariable Two-Sample MR (TSMR) was used to estimate the total causal effects of antibody immune response on ANDs, we applied five MR analysis methods: IVW, MR Egger, Weighted Median, Simple Mode, and Weighted Mode, IVW served as the primary approach for result interpretation [26].

To clarify whether there were reverse causal relationships between ANDs andantibody immune responses, we also conducted reverse Mendelian randomization.

174 To account for multiple comparisons, the Bonferroni correction was utilized. We set a 175 significance threshold of  $\alpha = 0.05/n$  (where n represents the number of comparisons) to

mitigate the increased risk of false positives from multiple testing [27]. This correction method helps maintain the overall Type I error rate at an acceptable level while controlling for the familywise error rate. Therefore, a P-value below 4.55E-04 (calculated as 0.05 divided by the product of 22 comparisons and 5 outcomes) was considered statistically significant.

181 MR Egger intercept test and Outlier (MR-PRESSO) were used to detect the 182 presence of pleiotropy, When the P-values for MR Egger intercept and MR-PRESSO are less than or equal to 0.05, it suggests the presence of pleiotropic IVs. To address this, we 183 184 iteratively performed MR Egger intercept and MR-PRESSO tests, removing any outliers each time, until no horizontal pleiotropy was detected. Furthermore, we also employed 185 186 visual inspection of the scatter plot and forest plot to test the MR "no horizontal 187 pleiotropy". Additionally, Cochran's Q statistic was used to assess the degree of heterogeneity among all IVs. P-value from the Q-test greater than 0.05 indicates that 188 189 there is no significant heterogeneity among the IVs.

To assess the robustness of the identified causal associations, we conducted two sensitivity analyses: the MR-Egger intercept test and leave-one-out analysis. The intercept from the MR-Egger test estimates the degree of directional pleiotropy, while the leave-one-out analysis determines if the significant results are influenced by any single SNP.

## 195 **Meta-analysis**

For MS and MG, when the MR results of the discovery and replication phases wereinconsistent, the meta-analysis was performed to assess combined causality. The choice

- 198 of effect model was based on the heterogeneity of the results. If there was little significant
- 199 heterogeneity with  $12 \le 50\%$ , the fixed-effects model was used to combine the results.

200 Otherwise, the random effects model was used.

- 201 The statistical analyses in this study were performed using R version 4.4.1, including
- 202 TwoSampleMR, MRPRESSO and Metafor. The study protocol and details were not pre-

203 registered

204 **Results** 

## 205 Selection of Instrumental Variables

206 Detailed information on the IVs of antibody immune responses to five types of herpesvirus is shown in Supplementary Table 2. The P value thresholds for anti-CMV 207 208 IgG seropositivity, CMV pp28 antibody levels, CMV pp52 antibody levels, CMV pp150 209 antibody levels, anti-EBV IgG seropositivity, anti-HHV6 IgG seropositivity, anti-HHV6 IE1A IgG seropositivity, HHV6 IE1A antibody levels, anti-HHV6 IE1B IgG seropositivity, 210 211 HHV6 IE1B antibody levels, HPV6 p101k antibody levels, anti-HHV7 IgG seropositivity, 212 anti-HSV 1 IgG seropositivity, HSV1 mgG-1 antibody levels anti-HSV2 IgG seropositivity 213 and HSV2 mgG-1 antibody levels were 1e-05, HHV7 U14 antibody levels were 1e-07, 214 EBV EA-D antibody levels, EBV EBNA-1 antibody levels, EBV VCA p18 antibody levels, 215 EBV ZEBRA antibody levels and VZV qE and qI antibody levels were 5e-08. rs1808192 216 in HHV7 U14 antibody levels, rs34811474 in anti-HSV 1 IgG seropositivity and 217 rs13204572 in VZV gE and gI antibody levels were deleted as they were associated with 218 BMI. IVs for MS, NMO, MG, CIDP, GBS are shown in Supplementary Tables 3, 5, 7, 9, 11, respectively. All F values of the IVs were greater than 10, indicating that weak 219

220 instruments were excluded.

# Antibody Immune Response Following Herpesvirus Infection on MS

223 In this study, the antibody unit was the logarithmic transformation of the antibody median 224 fluorescence intensity. We observed a causal effect of a 1-unit increase in EBV EBNA-1 225 antibody levels, EBV VCA p18 antibody levels and HHV7 U14 antibody levels correlating 226 with an increasing risk of MS [IVW: odds ratio (OR) = 3. 009, 95% CI: 2.377-3.807, P=4.772e-20, adjusted p=2.250e-18; IVW: OR=8.700, 95% CI: 6.128-12.351, P=1.059e-227 228 33, adjusted p=1.165e-31 and IVW: OR=3.359, 95%CI: 2.034-5.546, P=2.187e-06, 229 adjusted p=2.406e-04]. In addition, causal evidence was also found for a differential 230 effect of a 1-unit increase in EBV ZEBRA antibody levels (IVW: OR = 0.592, 95% CI: 231 0.491-0.713, P = 3.195e-08, adjusted p =3.515e-6), the analysis did not reveal causal relationships between other antibodies and the risk of MS (Fig 1, S Table 4). To validate 232 233 the above results, we also used the UK Biobank and FinnGen MS datasets, with detailed 234 results shown in Table 1. In all three datasets, the causal effects of EBV EBNA antibody 235 levels and EBV VCA p18 antibody levels on MS were significant; however, the MR results of HHV7 U14 antibody levels and EBV ZEBRA antibody levels on MS differed 236 237 between the three datasets, and the meta-analysis did not confirm that the overall effects 238 of these on MS were significant.

Exposure	Outcome	Method	Nsn	p pval		OR(95%CI)
Anti-CMV IgG seropositivity	MS	IVW	4	0.552	÷	1.040 (0.915- 1.181)
CMV pp28 antibody levels	MS	IVW	9	0.533	÷	1.043 (0.914– 1.190)
CMV pp52 antibody levels	MS	IVW	12	0.937	÷	1.005 (0.897- 1.125)
CMV pp150 antibody levels	MS	IVW	7	0.157	÷-	1.127 (0.955- 1.329)
Anti-EBV IgG seropositivity	MS	IVW	6	0.103	-	1.049 (0.990- 1.111)
EBV EA-D antibody levels	MS	IVW	3	0.001	-	0.544 (0.384- 0.773)
EBV EBNA-1 antibody levels	MS	IVW	7	4.772e-20		<b>——</b> 3.009 (2.377– 3.807)
EBV VCA p18 antibody levels	MS	IVW	8	1.059e-33		→ 8.700 (6.128-12.351)
EBV ZEBRA antibody levels	MS	IVW	5	3.195e-08	-	0.592 (0.491- 0.713)
Anti-HHV 6 IgG seropositivity	MS	IVW	7	0.614	÷	1.016 (0.954– 1.083)
Anti-HHV 6 IE1A IgG seropositivity	MS	IVW	7	0.759	÷	0.987 (0.908- 1.073)
HHV6 IE1A antibody levels	MS	IVW	10	0.909	÷	0.990 (0.826- 1.186)
Anti-HHV6 IE1B IgG seropositivity	MS	IVW	7	0.272		0.958 (0.887- 1.034)
HHV6 IE1B antibody levels	MS	IVW	11	0.372	4	0.954 (0.859- 1.058)
HHV6 p101k antibody levels	MS	IVW	11	0.372	÷	0.954 (0.859- 1.058)
Anti-HHV7 IgG seropositivity	MS	IVW	8	0.541	÷	0.988 (0.950- 1.028)
HHV7 U14 antibody levels	MS	IVW	2	2.187e-06		→ 3.359 (2.034-5.546)
Anti-HSV 1 IgG seropositivity	MS	IVW	9	0.498	÷	0.972 (0.895- 1.055)
HSV1 mgG-1 antibody levels	MS	IVW	14	0.569	÷	1.032 (0.925- 1.152)
Anti-HSV2 IgG seropositivity	MS	IVW	7	0.528	÷	1.034 (0.931- 1.149)
HSV2 mgG-1 antibody levels	MS	IVW	13	0.314		0.971 (0.917- 1.028)
VZV gE and gI antibody levels	MS	Wald ratio	1	0.001 I		0.106 (0.028- 0.406)

## 239

#### Fig 1 : MR estimate results of antibodies of five herpesviridae viruses on MS. 240

241 Table 1. Mendelian Randomization Analysis of the Causal Effects of Herpesvirus Antibodies on

242 Multiple Scielosis Kisk Across Different Datase	242	Multiple Sclerosis Risk Across Different Data	asets
---	-----	---	-------

Exposure	Outcome	datasets	Method	OR (95%CI)	Р	Adjusted P
EBV EBNA-1	MS	IMSGC	IVW	3.009(2.377-3.807)	4.772e-20	2.250e-18
antibody levels		UK Biobank	IVW	1.004(1.003-1.005)	3.722e-27	/
		FinnGen	IVW	1.885(1.342-2.648)	2.534e-04	/
EBV VCA p18	MS	IMSGC	IVW	8.700(6.128-12.351)	1.059e-33	1.165e-31
antibody levels		UK Biobank	IVW	1.008(1.006-1.009)	2.275e-24	/
		FinnGen	IVW	6.888(4.725-10.041)	1.060e-23	/
HHV7 U14	MS	IMSGC	IVW	3.359 (2.034-5.546)	2.187e-06	2.406e-04
antibody levels		UK Biobank	IVW	0.100(0.998-1.002)	0.824	/
		FinnGen	IVW	1.208(0.802-1.820)	0.366	/
		Toal	REMA	1.647 (0.871-3.114)	0.234	/
		Heterogeneity	I <sup>2</sup> =93.38%	, τ <sup>2</sup> =0.369, P< 0.05		
EBV ZEBRA	MS	IMSGC	IVW	0.592(0.491-0.713)	3.195e-08	3.515e-6
antibody levels		UK Biobank	IVW	0.997(0.996-0.998)	3.589e-13	/

FinnGen	IVW	0.8/6(0.66/-1.151)	0.343	/
Toal	REMA	0.807(0.587 -1.109)	0.125	/
Heterogeneity:	I²=91.96%,	$\tau^2=0.070, P<0.05$		

243 Abbreviations: MS: multiple sclerosis: EBV: Epstein-Barr virus; HHV: human herpes virus; IVW: IVW: inverse

variance weighted; REMA: Random Effects Meta-Analysis.

## 245 Pleiotropy and Sensitivity Analysis for MS

246 Heterogeneity was observed among the IVs of EBV EBNA-1 antibody levels 247 (Q=27.055 P=1.414e-4), EBV VCA p18 antibody levels (Q=70.545 P=1.147e-12), HHV6 IE1A antibody levels (Q=17.036 P=0.048) and anti-HSV2 IgG seropositivity (Q=13.885 248 249 P=0.031) in terms of their effect on MS (S Table 4). All p-values from the MR Egger 250 intercepts and MR-PRESSO global tests were greater than 0.05, indicating the absence of outlier SNPs and no evidence of horizontal pleiotropy between the IVs and outcomes. 251 252 Leave-one-out analysis showed that the results remained consistent regardless of which 253 individual SNP was excluded (S Fig 1-22). 254 It is noteworthy that the final IVs of HHV7 U14 antibody levels and Varicella zoster 255 virus glycoproteins E and I (VZV gE and gl) antibody levels, filtered by the above steps, 256 consist of only two SNPs. IVs of the former have no heterogeneity (Q=2.823 P=0.093),

single SNP MR analysis showed the similar result (rs7773105: P=2.175e-05, adjusted

258 P=0.002, OR=2.562, 95%CI:1.660-3.956; rs805282: P=3.911e-12, adjusted P=4.300e-11,

OR=4.277, 95%CI: 2.97-6.448), we consider the causal relationship between HHV7 U14
antibody levels and MS to be reliable. However, there was significant heterogeneity

between these two IVs of VZV gE and gI antibody levels (Q= 53.561 P= 2.507e-13). In

the single SNP MR analysis, the significance of the effects of these two IVs on MS varied

263 (rs9270551: P = 2.78E-276, adjusted P = 3.058e-274, OR = 0.557e-06, 95% CI: 0.369e-03 - 0.843e-03; rs9272285: P = 1.052E-03, adjusted P = 0.116, OR = 0.106, 95% CI: 264 0.028-0.406). In particular, rs9270551 was strongly associated with MS (P = 1E-200), 265 266 suggesting the presence of horizontal pleiotropy. Therefore, based on the MISGC databases, we used rs9272285 as an IV for VZV gE and gI antibody levels for MS. To 267 268 further investigate the association between VZV gE and gI antibody levels and MS, we 269 also performed MR analysis based on the MS datasets in UK Biobank and FinnGen with 270 the following results: OR (95%CI) =1.000(0.999-1.001), P=0.299 (UK Biobank), 271 0.2171830962485 OR (95%CI) =0.820 (0.5978-1.124) P=0.217 (FinnGen), so there 272 wasn't the causal relationship between VZV gE and gI antibody levels and MS.

## 273 MS on Antibody Immune Response

274 Reverse Mendelian randomization revealed that MS does not have significant 275 reverse causal effects on antibodies to the aforementioned herpesvirus antigens, with all 276 p-values greater than the adjusted p-value (4.550e-04) (S Fig 23).

## 277 Antibody Immune Response on NMO

There is a causal relationship between elevated levels of two EBV-related antibodies and a reduced risk of NMO. These two antibodies are EBV EA-D antibody levels (IVW: OR = 0.043 95% CI: 0.010-0.196, P = 4.546e-05, adjusted p=0.005) and EBV ZEBRA antibody levels (IVW: OR = 0.079, 95% CI: 0.043-0.147, P = 7.587e-16, adjusted p=8. 345e-14). Conversely, an increased risk of NMO could be caused by higher antibody levels of HHV7 U14 (IVW: OR =10.641 95% CI: 3.025-37.429, P=2.285e-04 adjusted p=0.025) or VZV gE and gI (IVW: OR =17.220 95% CI: 9.760-30.380, P=8.727e-23

285 adjusted p=9.599e-21). Antibodies to other viruses of the Herpesviridae family had no

286 causal effect on the risk of NMO (Fig 2, S Table 6).

Exposure	Outcome	Method	Nsnp	pval		OR(95%CI)
Anti-CMV IgG seropositivity	NMO	IVW	8	0.382		0.757 (0.405- 1.414)
CMV pp28 antibody levels	NMO	IVW	12	0.812	<b>—</b>	1.080 (0.574- 2.031)
CMV pp52 antibody levels	NMO	IVW	15	0.579		0.840 (0.453- 1.558)
CMV pp150 antibody levels	NMO	IVW	6	0.843	<u> </u>	0.907 (0.345- 2.383)
Anti-EBV IgG seropositivity	NMO	IVW	9	0.368	+	1.108 (0.886- 1.385)
EBV EA-D antibody levels	NMO	IVW	4 4	.546e-05 <b>=</b>		0.043 (0.010- 0.196)
EBV EBNA-1 antibody levels	NMO	IVW	21	0.692	-	0.889 (0.498- 1.589)
EBV VCA p18 antibody levels	NMO	IVW	19	0.016	<b>-</b>	0.389 (0.181- 0.840)
EBV ZEBRA antibody levels	NMO	IVW	19 7.	.587e-16 =		0.079 (0.043- 0.147)
Anti-HHV 6 IgG seropositivity	NMO	IVW	10	0.840	+	0.975 (0.761- 1.248)
Anti-HHV 6 IE1A IgG seropositivity	NMO	IVW	14	0.026	+	0.628 (0.416- 0.947)
HHV6 IE1A antibody levels	NMO	IVW	20	0.006	•	0.281 (0.113- 0.698)
Anti-HHV6 IE1B IgG seropositivity	NMO	IVW	14	0.614	÷	0.920 (0.665- 1.273)
HHV6 IE1B antibody levels	NMO	IVW	20	0.385		0.710 (0.327- 1.539)
HHV6 p101k antibody levels	NMO	IVW	9	0.588	+	1.129 (0.728- 1.753)
Anti-HHV7 IgG seropositivity	NMO	IVW	15	0.700	÷	1.079 (0.733- 1.588)
HHV7 U14 antibody levels	NMO	IVW	5 2	.285e-04		<ul> <li>10.641 (3.025–37.429)</li> </ul>
Anti-HSV 1 IgG seropositivity	NMO	IVW	11	0.752	- <b>-</b> -	0.924 (0.566- 1.508)
HSV1 mgG-1 antibody levels	NMO	IVW	22	0.019	-	0.535 (0.317- 0.902)
Anti-HSV2 IgG seropositivity	NMO	IVW	10	0.739	÷	1.056 (0.766- 1.455)
HSV2 mgG-1 antibody levels	NMO	IVW	16	0.625	+-	1.074 (0.806- 1.432)
VZV gE and gI antibody levels	NMO	IVW	14 8	<b>8.727е-23</b> Г 0		▶ 17.220 (9.760-30.380) 1 4

287

Fig 2 MR estimate results of antibodies of five herpesviridae viruses on NMO. 288

#### Pleiotropy and Sensitivity Analysis for NMO 289

290 Heterogeneity was observed in the IVs for EBV EA-D antibody levels (Q=6.892, 291 P=0.075), EBV EBNA-1 antibody levels (Q=70.545, P=6.776e-4), EBV ZEBRA antibody levels (Q=34. 471, P=0.011), HHV6 IE1A antibody levels (Q=29.584, P=0.042) and 292 293 HHV6 IE1B antibody levels (Q=31.661, P=0.034) on NMO (Supplementary Table 6). The MR-PRESSO global test indicated the presence of horizontal pleiotropy between the IVs 294 295 for EBV EBNA-1 antibody levels on NMO (P=0.001), EBV ZEBRA antibody levels 296 (P=0.022) and HHV6 IE1B antibody levels (P=0.034). However, the p-values of the 297 Egger intercept were greater than 0.05 and no significant outliers were detected. The 298 leave-one-out analysis confirmed that no single SNP significantly altered the overall

299 results. Therefore, the results still have some informative value.

300	For the IVs of EBV ZEBRA antibody levels, the p-value of the MR-PRESSO global
301	test was less than 0.05, but the Egger intercept was greater than 0.05. All five MR
302	statistical methods showed a consistent direction of effect, similar effect estimates and
303	OR values (Supplementary Table 6). The leave-one-out analysis again showed that the
304	results were robust to the exclusion of any single SNP (Supplementary Fig 9). Thus, the
305	overall results continue to support the existence of a causal relationship between EBV

306 ZEBRA antibody levels and NMO.

307 Pleiotropy tests for the IVs of other antibodies showed no outlier SNPs and no

308 evidence of horizontal pleiotropy between them and the outcomes (Supplementary Table

309 6). Leave-one-out analysis consistently showed that excluding any single SNP did not

310 affect the results (S Fig 1-22).

## 311 NMO on Antibody Immune Response

312 Reverse causal effects of NMO on antibodies were not found (S Fig 24).

## 313 Antibody Immune Response on MG

We found a causal effect between increased VZV gE and gI antibody levels and an increased risk of MG (IVW: OR = 2.542 95% CI: 1.972-3.277, P =5.897e-13 adjusted p= 2.594e-12). No significant associations were found between other antibodies and MG (Fig 3). In addition, the UK Biobank and FinnGen MG datasets were used to validate this result, with detailed results shown in Table 2. In all three datasets, the causal effect of VZV gE and gI antibody levels on MG was all significant.

Exposure	Outcome	Method	Nsnp	pval		OR(95%CI)
Anti-CMV IgG seropositivity	MG	IVW	13	0.880	+	0.989 (0.860-1.138)
CMV pp28 antibody levels	MG	IVW	18	0.369	-	1.085 (0.908-1.296)
CMV pp52 antibody levels	MG	IVW	24	0.485	÷	1.060 (0.900-1.250)
CMV pp150 antibody levels	MG	IVW	8	0.938	+	1.013 (0.735-1.396)
Anti-EBV IgG seropositivity	MG	IVW	13	0.057		1.063 (0.998-1.131)
EBV EA-D antibody levels	MG	IVW	3	0.004 -	-	0.414 (0.229-0.751)
EBV EBNA-1 antibody levels	MG	IVW	24	0.058	-	1.172 (0.994–1.382)
EBV VCA p18 antibody levels	MG	IVW	10	0.457	+	1.105 (0.850-1.437)
EBV ZEBRA antibody levels	MG	IVW	19	0.366	+	1.093 (0.901-1.326)
Anti-HHV 6 IgG seropositivity	MG	IVW	13	0.497	÷	1.035 (0.937-1.144)
Anti-HHV 6 E1A IgG seropositivity	MG	IVW	13	0.096	-	1.097 (0.984-1.223)
HHV6 IE1A antibody levels	MG	IVW	16	0.103	-	1.205 (0.963-1.509)
Anti-HHV6 IE1B IgG seropositivity	MG	IVW	18	0.677	+	0.980 (0.893-1.076)
HHV6 IE1B antibody levels	MG	IVW	28	0.408	+	0.923 (0.765-1.115)
HPV6 p101k antibody levels	MG	IVW	20	0.803	÷	1.013 (0.917-1.118)
Anti-HHV7 IgG seropositivity	MG	IVW	18	0.847	÷	1.005 (0.955-1.058)
HHV7 U14 antibody levels	MG	IVW	8	0.834	+-	1.043 (0.706-1.539)
Anti-HSV 1 IgG seropositivity	MG	IVW	15	0.459	÷	1.050 (0.923-1.194)
HSV1 mgG-1 antibody levels	MG	IVW	27	0.839	+	1.017 (0.866-1.194)
Anti-HSV2 IgG seropositivity	MG	IVW	17	0.124	•	1.067 (0.982-1.160)
HSV2 mgG-1 antibody levels	MG	IVW	21	0.927	÷	0.996 (0.914-1.085)
VZV gE and gI antibody levels	MG	IVW	12 <b>5</b>	5.897e-13		2.542 (1.972-3.277) I

320

- Fig 3 MR estimate results of antibodies of five herpesviridae viruses on MG. 321
- 322 Table 2. MR estimate results of antibodies of VZV gE and gI antibody levels on MG.

Exposure	Outcome	Author and	Method	OR (95%CI)	Р	Adjusted P
		datasets				
VZV gE and	MG	Jiang L et al.	IVW	2.542(1.972-3.277)	5.897e-13	2.594e-12
gI antibody		UK Biobank	IVW	1.00024(1.000035-	0.022	/
levels		OK BIODalik		1.000445)		
		FinnGen	IVW	2.619(1.768-3.880)	1.576e-06	/

323 Abbreviations: MG: myasthenia gravi; VZV: varicella zoster virus; IVW: inverse variance

324 weighted; REMA: random effects meta-Analysis.

### Pleiotropy and Sensitivity Analysis for MG 325

326 IVs of EBV EA-D antibody levels (Q=44.715, P=0.004) and EBV ZEBRA antibody levels (Q=37.615, P=0.004) show significant heterogeneity (Supplementary Table 8). 327 328 Although MR-PRESSO identified pleiotropy, the Egger intercept did not indicate

significant pleiotropy and no significant outliers were detected. IVs from other antibodies
did not show heterogeneity and pleiotropy (S Table 8). The leave-one-out analysis gave
similar results, even after excluding individual SNPs (S Fig 1-22).

332 MG on Antibody Immune Responses

The adjusted P values from the MR analysis indicated that there was no causal relationship between MG and any of the 22 types of antibody immune response (S Fig 24).

336 Causal Relationships Detected Between Antibody
 337 Immune Responses and GBS/CIDP

We found no forward or reverse causal relationships between the 22 antibody immune responses to five types of herpesviruses and GBS and CIDP (Fig 4-5 ; S Fig 26-27). IVs for HSV1 mgG-1 antibody levels on CIDP showed heterogeneity (Q = 44.905, P = 0.03) (S Table 12). Pleiotropy was detected by MR-PRESSO but not by the Egger intercept, and the MR-PRESSO global test did not identify any significant outliers. Leaveone-out analysis showed no significant differences in MR results after removing individual SNPs (S Fig 1-22).

Exposure	Outcome	Method	Nsnp	pval		OR(95%CI)
Anti-CMV IgG seropositivity	GBS	IVW	13	0.083	<b>⊢</b> ∎—	1.266 (0.970-1.653)
CMV pp28 antibody levels	GBS	IVW	19	0.469		1.129 (0.814-1.566)
CMV pp52 antibody levels	GBS	IVW	21	0.335		1.157 (0.860-1.557)
CMV pp150 antibody levels	GBS	IVW	8	0.713		1.103 (0.655-1.856)
Anti-EBV IgG seropositivity	GBS	IVW	12	0.442	+	0.952 (0.840-1.079)
EBV EA-D antibody levels	GBS	IVW	10	0.792	<b>—</b>	1.054 (0.715-1.553)
EBV EBNA-1 antibody levels	GBS	IVW	36	0.079		0.849 (0.708-1.019)
EBV VCA p18 antibody levels	GBS	IVW	17	0.003		0.643 (0.479-0.863)
EBV ZEBRA antibody levels	GBS	IVW	25	0.967	-+	1.005 (0.782-1.292)
Anti-HHV 6 IgG seropositivity	GBS	IVW	13	0.539	-	0.961 (0.846-1.092)
Anti-HHV 6 IE1A IgG seropositivity	GBS	IVW	22	0.622	-	0.959 (0.813-1.132)
HHV6 IE1A antibody levels	GBS	IVW	24	0.861	_ <b>i</b>	1.029 (0.748-1.416)
Anti-HHV6 IE1B IgG seropositivity	GBS	IVW	19	0.872	- <b>-</b>	1.015 (0.843-1.222)
HHV6 IE1B antibody levels	GBS	IVW	29	0.794		0.959 (0.698-1.317)
HHV6 p101k antibody levels	GBS	IVW	21	0.766	-4-	0.975 (0.824-1.153)
Anti-HHV7 IgG seropositivity	GBS	IVW	19	0.204	+	1.049 (0.974-1.130)
HHV7 U14 antibody levels	GBS	IVW	9	0.068		0.629 (0.383-1.035)
Anti-HSV 1 IgG seropositivity	GBS	IVW	16	0.308		0.896 (0.725-1.107)
HSV1 mgG-1 antibody levels	GBS	IVW	31	0.312	+	1.157 (0.872-1.535)
Anti-HSV2 IgG seropositivity	GBS	IVW	16	0.533	- <b>e</b>	1.063 (0.876-1.290)
HSV2 mgG-1 antibody levels	GBS	IVW	21	0.662	+-	1.034 (0.891-1.199)
VZV gE and gl antibody levels	GBS	IVW	19	0.878 F 0		0.977 (0.723–1.319) 1 2

Fig 4 MR estimate results of antibodies of five herpesviridae viruses on GBS.

Exposure	Outcome	Method	Nsnp	pval		OR(95%CI)
Anti-CMV IgG seropositivity	CIDP	IVW	14	0.713	+	1.042 (0.837-1.298)
CMV pp28 antibody levels	CIDP	IVW	20	0.492	_ <b>_</b>	0.912 (0.702-1.186)
CMV pp52 antibody levels	CIDP	IVW	24	0.623		1.067 (0.823-1.384)
CMV pp150 antibody levels	CIDP	IVW	8	0.930	<b>i</b>	0.974 (0.541-1.753)
Anti-EBV IgG seropositivity	CIDP	IVW	14	0.576	÷	0.974 (0.886-1.069)
EBV EA-D antibody levels	CIDP	IVW	14	0.867	- <b>+</b>	1.026 (0.762-1.381)
EBV EBNA-1 antibody levels	CIDP	IVW	44	0.148		0.914 (0.809-1.033)
EBV VCA p18 antibody levels	CIDP	IVW	20	0.165	- <b>-</b> +	0.850 (0.675-1.069)
EBV ZEBRA antibody levels	CIDP	IVW	32	0.724	<b>+</b>	0.972 (0.832-1.136)
Anti-HHV 6 IgG seropositivity	CIDP	IVW	13	0.174		0.921 (0.818-1.037)
Anti-HHV 6 IE1A IgG seropositivity	CIDP	IVW	23	0.447	+	0.943 (0.812-1.096)
HHV6 IE1A antibody levels	CIDP	IVW	26	0.032	<b></b>	1.335 (1.025–1.738)
Anti-HHV6 IE1B IgG seropositivity	CIDP	IVW	22	0.101		0.895 (0.784-1.022)
HHV6 IE1B antibody levels	CIDP	IVW	30	0.342	<b></b>	0.885 (0.689-1.138)
HPV6 p101k antibody levels	CIDP	IVW	21	0.382		0.930 (0.791-1.094)
Anti-HHV7 IgG seropositivity	CIDP	IVW	17	0.509	÷	1.027 (0.949-1.111)
HHV7 U14 antibody levels	CIDP	IVW	9	0.767	_ <del></del>	1.071 (0.681-1.685)
Anti-HSV 1 IgG seropositivity	CIDP	IVW	14	0.422		1.087 (0.886-1.334)
HSV1 mgG-1 antibody levels	CIDP	IVW	30	0.401		0.877 (0.646-1.191)
Anti-HSV2 IgG seropositivity	CIDP	IVW	15	0.883	<b>.</b>	0.989 (0.856-1.143)
HSV2 mgG-1 antibody levels	CIDP	IVW	22	0.652	-	0.964 (0.820-1.132)
VZV gE and gI antibody levels	CIDP	IVW	26	0.869		1.016 (0.843-1.224) 1 2

Fig 5 MR estimate results of antibodies of five herpesviridae viruses on CIDP. 

All other results, including those for GBS and CIDP, passed the heterogeneity and pleiotropy tests. The sensitivity analysis did not identify any SNPs that significantly affected the overall results.

352 **Dicussion** 

As the MR results showed, EBV EBNA-1 antibody and VCA p18 antibody were positively correlated with MS. Levels of EBV ZEBRA antibody were negatively correlated with MS in the IMSGC and UK Biobank datasets, but not in FinnGen, and the metaanalyses did not confirm a causal relationship. In addition, HHV7 U14 antibody levels were positively associated with MS in the IMSGC dataset, but not in the UK Biobank or FinnGen datasets, and the overall causal relationship was not established by the metaanalyses.

Negative associations between EBV ZEBRA and EA-D antibody levels and NMO were shown in this study. Conversely, a positive association was found between NMO and antibody levels of VZV gE, VZV gI and HHV7 U14. VZV gE and gI antibody levels showed a positive association with MG.

The above results suggest an important role for EBV antigen-associated antibodies in the pathogenesis of AND. EBV infects and persists in human B cells by exploiting the B cell environment to sustain its life cycle while evading the host immune system through minimal expression of viral proteins [28]. Several antibodies to EBV proteins can be detected in EBV carriers. These proteins include EBNA-1 (BKRF1), a latency protein; VCA p18 (BFRF3), a structural protein of the mature virus; ZEBRA (BZLF1), a lytic cycle protein; and EA-D, a basic component of the viral DNA replication complex. [28, 29].

371 Previous studies have confirmed that higher antibody levels against EBNA-1 and VCA 372 p18 (or VCA) are associated with an increased risk of MS; in individuals with genetic 373 factors associated with lower EBNA-1 IgG titres, the onset of MS was delayed by 3.5 374 years [30, 31], [32]. A region within the carboxyl half of EBNA1 (amino acids 385-420) 375 induces elevated antibody levels in MS patients and shows the strongest association with 376 MS risk compared to antibody levels against other domains of EBNA1 [33]. EBNA1-377 specific antibodies are found in the cerebrospinal fluid (CSF) of some MS patients; these 378 antibodies may play a role in the formation of oligoclonal bands, which are antibodies 379 produced by clonal B-cell-derived plasma cells in the central nervous system and are a 380 hallmark of MS [34]. Injection of a peptide derived from the aa395-420 region of EBNA1 381 into mice with experimental autoimmune encephalomyelitis (EAE) exacerbated CNS 382 autoimmunity [34, 35].

383 Our research confirms a causal relationship between antibodies to EBNA-1 or VCA p18 384 and MS. However, the exact mechanisms by which these two antibodies cause MS are 385 not yet clear. Based on the current evidence, molecular mimicry of EBNA-1 and VCA 386 p18 may play some role.Antibodies against VCA p18 (BFRF3) cross-react with the 387 cytoplasmic protein septin-9 [36]. Septin-9, a cytoplasmic protein that forms filaments, 388 may play a role in cytokinesis, exocytosis, neurite outgrowth and cell cycle control. While 389 it is widely expressed in various tissues, it is emerging as an intriguing candidate 390 autoantigen for MS due to gene mutations that cause hereditary neuralgic amyotrophy 391 [37]. In the CNS, septin-9 is mainly found in neurons and its expression is upregulated 392 after trauma [38]. Antibodies to EBNA1 have been observed to cross-react with

393 anoctamin 2, aB-crystallin, myelin basic protein (MBP) and glial cell adhesion molecule 394 [33, 34, 39]. However, the pathogenic role of these antibodies remains unclear because 395 successful cell-depleting therapy for MS does not affect antibody-producing plasma cells 396 in the short term. Moreover, such treatment does not seem to reduce oligoclonal bands 397 [7]. These two antibodies may become new therapeutic targets in MS, particularly in 398 patient groups with high levels of these antibodies and poor response to other treatments. 399 ZEBRA (BZLF1) was considered to be a major environmental factor associated with 400 MS and a significant contributor to the disease process [40]. BZLF1 was found in 46% of 401 MS brains, mainly associated with chronic lesions, and in 44% of non-MS brain tissue 402 [41]. ZEBRA is recognised as one of the viral immediate early genes that play an 403 important role in the transition of EBV from latency to lytic replication [42], Reactivation of 404 latent EBV infection is associated with disease activity in MS patients; however, research results are controversial [43-45]. Meanwhile, increasing EBV ZEBRA antibodies have not 405 406 been found in MS [46], the role of ZEBRA antibodies in MS remains unclear.

407 Previous research found that anti-EA seropositivity was significantly higher in the 408 NMOSD group compared to the HC group and MS patients [47, 48], but another study 409 suggested that exposure to Epstein-Barr virus was not associated with an increased 410 likelihood of NMO compared to healthy subjects [49]. Although our research suggests 411 that BV ZEBRA and EA-D antibody levels may be associated with a reduced risk of NMO, 412 further studies are needed to confirm this. Based on the advantages of MR statistics, this 413 study suggests that EBV antibodies may provide new clues for NMO treatment. In 414 particular, for NMO patients with high levels of EBV antibodies, understanding the

415 different roles of different antibodies in the pathogenesis of NMO may facilitate the416 exploration of personalised treatment approaches.

Current research on the association between HHV infection and the risk of MS has yielded controversial results, [50-52], This controversy is reflected in the results of this MR analysis. A meta-analysis found that CMV IgG seroprevalence was lower in people with MS than in controls in Europe [53]. However, our study does not support a causal relationship between CMV antibody immune response and risk of MS. Although one MR study suggested a causal relationship between herpesvirus infection and MS, we did not

423 find a causal relationship between VZV gE and gI antibody levels and MS [18].

424 At present, the relationship between HHV and NMO is not very clear. Our study 425 suggests that HHV may be one of the important pathogens of NMO, and HHV 7 U14 426 antibody may be detrimental to NMO, but its exact pathogenic role in NMO requires further investigation. VZV has been considered as a precursor infectious agent of NMO 427 428 [54-56], Causal association between chickenpox infection and NMO was also recently 429 confirmed by MR study [57], Our study further confirmed a causal effect of VZV gE and gI 430 antibody levels on NMO. VZV infection is an important risk factor for NMO, and 431 vaccination against VZV may help to reduce the risk of NMO. For NMO patients with high 432 levels of VZV qE and qI antibodies, the immune response and related pathogenic 433 mechanisms induced by VZV infection could potentially become a new therapeutic 434 approach.

435 Among 22 types of antibody immune response, only VZV gE and gI antibody levels 436 were found to be associated with MG. The resultant GWAS data from two different

datasets both confirm this causal association, suggesting that unlike in MS, the
pathogenic role of VZV in MG was robust, which may imply new therapeutic targets for
MG, especially for patients with high levels of this antibody.

440 This study has a number of important strengths. First, we effectively reduced the influence of confounding factors and improved the accuracy and reliability of our results 441 442 by using a novel MR analysis method. Second, our comprehensive analysis explored the 443 causal relationships between 22 antibody immune responses to five herpesvirus infections and five types of ANDs. This provided a detailed understanding of their 444 445 interactions. Third, we applied a rigorous correction procedure to ensure the robustness 446 and validity of our findings. For positive results, we cross-validated with additional 447 publicly available GWAS outcome data. We also conducted further meta-analyses to 448 resolve any inconsistencies. These measures helped to reduce the risk of false positives. They also strengthened the credibility of our conclusions. 449

450 Although this study provides valuable insights, it has several limitations that should 451 be acknowledged. First, the use of summary level data in MR analyses, although 452 powerful, may introduce bias due to the assumption of linearity and the inability to 453 explore non-linear relationships. In addition, the generalisability of the findings is limited 454 by the demographic and genetic composition of the datasets used, which are 455 predominantly of European ancestry. This raises questions about the applicability of the results to more diverse populations. Another limitation is the potential for pleiotropy, 456 457 where genetic variants used as instruments may affect the outcome through pathways 458 other than the exposure of interest, leading to biased estimates. Although we used

methods to mitigate pleiotropy, such as MR-PRESSO, the possibility of residual confounding cannot be completely excluded. Finally, the study relies on the availability and quality of existing GWAS datasets, which may vary in their coverage and accuracy of antibody measurements, potentially affecting the robustness of the findings. Future studies should aim to validate these findings in more diverse populations and with individual-level data to better understand the complex relationships between herpesvirus antibodies and autoimmune neurodegenerative diseases.

## 466 **Conlusion**

The results of this study reveal predicted causal effects of EBV EBNA-1 antibody, EBV VCA p18 antibody on MS, HHV7 U14, VZV gE and gl antibody, EBV EA-D antibody and EBV ZEBRA antibody on NMO, VZV gE and gl antibody on MG, This might suggest potential role for above antibodies in the pathogenesis of ANDs, also This finding highlights the need for further exploration into the specific mechanisms of above antibodies in the pathophysiological processes of ANDs, providing an important theoretical basis for the development of more effective treatment strategies in the future.

474

## 475 **Declarations**

## 476 Ethics approval and consent to participate

Publicly available datasets were used for all data in our study. Informed consent was
obtained from all participants prior to enrollment, and ethical approval was obtained for
each cohort.

#### Consent for Publication 481

482 All authors provide their consent for the publication of this manuscript.

483

#### Availability of data and materials 484

The original papers presented in this study can be found in the supplementary materials. 485

486

#### **Competing Interests** 487

- 488 The authors declare that they have no competing interests. The research, data
- 489 interpretation, and conclusions presented in this manuscript were not influenced by any
- 490 financial, personal, or professional conflicts.

491

#### Funding 492

- Grant from Science and Technology Program of Guangzhou : Key Lab of Guangzhou 493
- 494 Basic and Translational Research of Pan-vascular Diseases (202201020042); Youth
- 495 Pre-employment Training Programme Research Fund (2023ZC07); Natural Science

496 Foundation of Hunan Province - Regional Joint Fund (2024JJ7012).

497

#### Authors' contributions 498

- 499 Sunjun Sun: Writing - original draft, Visualization, Validation, Methodology, Formal
- 500 analysis, Funding acquisition;
- 501 Yiyong Wen: Writing- original draft, Formal analysis, review & editing;
- Pan Tang: Writing- review & editing, Validation. 502

- 503 Fan Xie: Writing review & editing, Visualization, Validation.
- 504 Jun Wen: Writing review & editing, Supervision,
- 505 Anding Xu: Writing -Conceptualization, review & editing, Supervision, Funding
- 506 acquisition. Project administration.
- 507 Acknowledgements

The authors thank the Multiple Sclerosis Genetics Consortium and the International Myasthenia Gravis Genomics Consortium, the UK Biobank and the FinnGen study for providing publicly available MS, MG and GBS GWAS summary statistics for this analysis , as well as the studies by Butler-Laporte G et al, Estrada K et al, Chia R et al, Jiang L et al for antibody immune responses to five types of herpesvirus, NMO, MG, CIDP GWAS summary statistics.

514

515 List of abbreviations

516 ANDs: Autoimmune neuroinflammatory diseases , MS: multiple sclerosis, NMO: 517 neuromyelitis optica, GBS: Guillain-Barr é syndrome, CIDP: chronic inflammatory 518 demyelinating polyneuropathy, MG: myasthenia gravis. CNS: central nervous system, PNS: peripheral nervous system, NJM: neuromuscular junction. EBV: Epstein-Barr virus; 519 520 HHV 6A: Human herpesvirus 6A; CMV: Cytomegalovirus; AQP4 lgG+ NMOSD: 521 aquaporin-4 antibody-positive NMO spectrum disord, MR: mendelian randomisation, 522 HSV: herpes simplex virus, EBNA-1: EBV encoded nuclear antigen-1, EBV-VCA p18: 523 EBV viral capsid antigen p18,VZV gE and gI: Varicella zoster virus glycoprotein E and I, GWAS: Genome-Wide Association Study; IMSGC: International MS Genetics 524

525 Consortium; anti-AChR: anti-acetylcholine receptor antibodies; anti-MuSK: antibodies to 526 muscle-specific kinase; SNPs: single nucleotide polymorphisms; MAF: minor allele 527 frequencies; LD: linkage disequilibrium; BMI: body mass index; IVW: Inverse Variance 528 Weighte; IVs: instrumental variables (IVs); TSMR: Two-Sample MR; MR-PRESSO: MR 529 Egger intercept test and Outlier; OR: odds ratio; CSF: cerebrospinal fluid; EAE: 530 experimental autoimmune encephalomyelitis.

## 531 **References**

Khan AW, Farooq M, Hwang MJ, Haseeb M, Choi S. Autoimmune Neuroinflammatory
 Diseases: Role of Interleukins. Int J Mol Sci. 2023;24(9). Epub 20230427. doi:
 10.3390/ijms24097960. PubMed PMID: 37175665; PubMed Central PMCID:
 PMCPMC10178921.

536 Bhagavati S. Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical 2. 537 Features, and Therapy. Front Neurol. 2021;12:664664. Epub 20210414. doi: 538 10.3389/fneur.2021.664664. PubMed PMID: 33935958; PubMed Central PMCID: 539 PMCPMC8079742.

540 3. Zarobkiewicz MK, Morawska I, Michalski A, Roliński J, Bojarska-Junak A. NKT and NKT-541 like Cells in Autoimmune Neuroinflammatory Diseases-Multiple Sclerosis, Myasthenia Gravis 542 and Guillain-Barre Syndrome. Int J Mol Sci. 2021;22(17). Epub 20210901. doi: 543 10.3390/ijms22179520. PMID: 34502425; PubMed PubMed Central PMCID: PMCPMC8431671. 544

545 4. Gogia B, Rocha Cabrero F, Khan Suheb MZ, Lui F, Rai PK. Chronic Inflammatory
546 Demyelinating Polyradiculoneuropathy. StatPearls. Treasure Island (FL): StatPearls

- 547 Publishing
- 548 Copyright © 2024, StatPearls Publishing LLC.; 2024.
- 549 5. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an
- 550 urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr
- 551 Opin Immunol. 2023;80:102266. Epub 20221126. doi: 10.1016/j.coi.2022.102266. PubMed
- 552 PMID: 36446151; PubMed Central PMCID: PMCPMC9918670.
- 553 6. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023;19(8):509-24.
- 554 Epub 20230510. doi: 10.1038/s41581-023-00720-1. PubMed PMID: 37165096; PubMed
- 555 Central PMCID: PMCPMC10171171.
- 556 7. Bjornevik K, Münz C, Cohen JI, Ascherio A. Epstein-Barr virus as a leading cause of
- 557 multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 2023;19(3):160-71. Epub
  558 20230209. doi: 10.1038/s41582-023-00775-5. PubMed PMID: 36759741.
- Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis
   reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science.
   2022;375(6578):296-301. Epub 20220113. doi: 10.1126/science.abj8222. PubMed PMID:
- **562 35025605**.

Miao Y, Shi Z, Zhang W, Zhu L, Tang S, Chen H, et al. Immune Repertoire Profiling
 Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum
 Disorders. Neurol Neuroimmunol Neuroinflamm. 2023;10(5). Epub 20230706. doi:
 10.1212/nxi.000000000200134. PubMed PMID: 37414573; PubMed Central PMCID:
 PMCPMC10326831.

568 10. Kuwabara S. Guillain-Barré syndrome: epidemiology, pathophysiology and management.

569 Drugs. 2004;64(6):597-610. doi: 10.2165/00003495-200464060-00003. PubMed PMID:
570 15018590.

571 11. Rodríguez Y, Vatti N, Ramírez-Santana C, Chang C, Mancera-Páez O, Gershwin ME,

572 Anaya JM. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J

573 Autoimmun. 2019;102:8-37. Epub 20190506. doi: 10.1016/j.jaut.2019.04.021. PubMed PMID:

574 31072742.

575 12. Kakalacheva K, Maurer MA, Tackenberg B, M ü nz C, Willcox N, L ü nemann JD.

576 Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann

577 Neurol. 2011;70(3):508-14. doi: 10.1002/ana.22488. PubMed PMID: 21905082.

578 13. Cavalcante P, Marcuzzo S, Franzi S, Galbardi B, Maggi L, Motta T, et al. Epstein-Barr 579 virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an

580 autoimmunity mediator? Oncotarget. 2017;8(56):95432-49. Epub 20170908. doi:

581 10.18632/oncotarget.20731. PubMed PMID: 29221139; PubMed Central PMCID:

582 PMCPMC5707033.

583 14. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian
584 randomization: using genes as instruments for making causal inferences in epidemiology.

585 Stat Med. 2008;27(8):1133-63. doi: 10.1002/sim.3034. PubMed PMID: 17886233.

586 15. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to

587 understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22. doi:

588 10.1093/ije/dyg070. PubMed PMID: 12689998.

589 16. Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent

590 Developments in Mendelian Randomization Studies. Curr Epidemiol Rep. 2017;4(4):330-45.

591 Epub 20171122. doi: 10.1007/s40471-017-0128-6. PubMed PMID: 29226067; PubMed

- 592 Central PMCID: PMCPMC5711966.
- 593 17. Zhang W, Wu P, Yin R, Sun M, Zhang R, Liao X, et al. Mendelian Randomization
- 594 Analysis Suggests No Associations of Herpes Simplex Virus Infections With Multiple Sclerosis.
- 595 Front Neurosci. 2022;16:817067. Epub 20220301. doi: 10.3389/fnins.2022.817067. PubMed
- 596 PMID: 35299622; PubMed Central PMCID: PMCPMC8920987.
- 597 18. Zhu G, Zhou S, Xu Y, Gao R, Zhang M, Zeng Q, et al. Chickenpox and multiple sclerosis:
- 598 A Mendelian randomization study. J Med Virol. 2023;95(1):e28315. Epub 20221123. doi:
- 599 10.1002/jmv.28315. PubMed PMID: 36380510.
- 600 19. Butler-Laporte G, Kreuzer D, Nakanishi T, Harroud A, Forgetta V, Richards JB. Genetic
- 601 Determinants of Antibody-Mediated Immune Responses to Infectious Diseases Agents: A
- 602 Genome-Wide and HLA Association Study. Open Forum Infect Dis. 2020;7(11):ofaa450.
- 603 Epub 20200924. doi: 10.1093/ofid/ofaa450. PubMed PMID: 33204752; PubMed Central
- 604 PMCID: PMCPMC7641500.
- 605 20. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in
- 606 susceptibility. Science. 2019;365(6460). doi: 10.1126/science.aav7188. PubMed PMID:
- 607 31604244; PubMed Central PMCID: PMCPMC7241648.
- 608 21. Estrada K, Whelan CW, Zhao F, Bronson P, Handsaker RE, Sun C, et al. A whole-
- 609 genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun.
- 610 2018;9(1):1929. Epub 20180516. doi: 10.1038/s41467-018-04332-3. PubMed PMID:
- 611 29769526; PubMed Central PMCID: PMCPMC5955905.
- 612 22. Chia R, Saez-Atienzar S, Murphy N, Chi ò A, Blauwendraat C, Roda RH, et al.

Identification of genetic risk loci and prioritization of genes and pathways for myasthenia
gravis: a genome-wide association study. Proc Natl Acad Sci U S A. 2022;119(5). doi:
10.1073/pnas.2108672119. PubMed PMID: 35074870; PubMed Central PMCID:
PMCPMC8812681.

617 23. Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for

618 biobank-scale data. Nat Genet. 2021;53(11):1616-21. Epub 20211104. doi: 10.1038/s41588-

619 021-00954-4. PubMed PMID: 34737426.

620 24. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with

multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658-65. Epub
20130920. doi: 10.1002/gepi.21758. PubMed PMID: 24114802; PubMed Central PMCID:

623 PMCPMC4377079.

Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, et al. A multivariate
genome-wide association analysis of 10 LDL subfractions, and their response to statin
treatment, in 1868 Caucasians. PLoS One. 2015;10(4):e0120758. Epub 20150421. doi:
10.1371/journal.pone.0120758. PubMed PMID: 25898129; PubMed Central PMCID:
PMCPMC4405269.

26. Sekula P, Del Greco MF, Pattaro C, Köttgen A. Mendelian Randomization as an
Approach to Assess Causality Using Observational Data. J Am Soc Nephrol.
2016;27(11):3253-65. Epub 20160802. doi: 10.1681/asn.2016010098. PubMed PMID:
27486138; PubMed Central PMCID: PMCPMC5084898.

633 27. Sedgwick P. Multiple hypothesis testing and Bonferroni's correction. Bmj.
634 2014;349:g6284. Epub 20141020. doi: 10.1136/bmj.g6284. PubMed PMID: 25331533.

635	28. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr
636	virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol.
637	2003;45(1):1-36. doi: 10.1016/s1040-8428(02)00078-1. PubMed PMID: 12482570.
638	29. Zhang Q, Holley-Guthrie E, Ge JQ, Dorsky D, Kenney S. The Epstein-Barr virus (EBV)
639	DNA polymerase accessory protein, BMRF1, activates the essential downstream component
640	of the EBV oriLyt. Virology. 1997;230(1):22-34. doi: 10.1006/viro.1997.8470. PubMed PMID:
641	9126259.

- 642 30. Dooley MM, de Gannes SL, Fu KA, Lindsey JW. The increased antibody response to
- 643 Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins. J Neuroimmunol.
- 644 2016;299:147-51. Epub 20160831. doi: 10.1016/j.jneuroim.2016.08.016. PubMed PMID:
- 645 27725113.

646 31. Huang J, Tengvall K, Bomfim Lima I, Hedström AK, Butt J, Brenner N, et al. Genetics of

647 immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis. Brain.

648 2024. Epub 20240417. doi: 10.1093/brain/awae110. PubMed PMID: 38630618.

649 32. Domínguez-Mozo MI, López-Lozano L, Pérez-Pérez S, García-Martínez Á, Torrejón MJ,

650 Arroyo R, Álvarez-Lafuente R. Epstein-Barr Virus and multiple sclerosis in a Spanish cohort:

A two-years longitudinal study. Front Immunol. 2022;13:991662. Epub 20220914. doi:

652 10.3389/fimmu.2022.991662. PubMed PMID: 36189297; PubMed Central PMCID:

653 PMCPMC9515943.

Bray PF, Luka J, Bray PF, Culp KW, Schlight JP. Antibodies against Epstein-Barr
nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities
between EBNA and myelin basic protein. Neurology. 1992;42(9):1798-804. doi:

657 10.1212/wnl.42.9.1798. PubMed PMID: 1381067.

- 658 34. Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. Clonally expanded
- B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321-7.
- 660 Epub 20220124. doi: 10.1038/s41586-022-04432-7. PubMed PMID: 35073561; PubMed
- 661 Central PMCID: PMCPMC9382663.
- 35. Kyllesbech C, Trier N, Slibinskas R, Ciplys E, Tsakiri A, Frederiksen JL, Houen G. Virusspecific antibody indices may supplement the total IgG index in diagnostics of multiple
  sclerosis. J Neuroimmunol. 2022;367:577868. Epub 20220418. doi:
- 665 10.1016/j.jneuroim.2022.577868. PubMed PMID: 35477126.
- 666 36. Lindsey JW. Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react
- 667 with human proteins. J Neuroimmunol. 2017;310:131-4. Epub 20170720. doi:
  668 10.1016/j.jneuroim.2017.07.013. PubMed PMID: 28778437.
- 669 37. Kuhlenbäumer G, Hannibal MC, Nelis E, Schirmacher A, Verpoorten N, Meuleman J, et
- 670 al. Mutations in SEPT9 cause hereditary neuralgic amyotrophy. Nat Genet.

671 2005;37(10):1044-6. Epub 20050925. doi: 10.1038/ng1649. PubMed PMID: 16186812.

672 38. Mao H, Liu J, Shi W, Huang Q, Xu X, Ni L, et al. The expression patterns of Septin-9

- after traumatic brain injury in rat brain. J Mol Neurosci. 2013;51(2):558-66. Epub 20130523.
- 674 doi: 10.1007/s12031-013-0024-6. PubMed PMID: 23700216.
- 39. Tengvall K, Huang J, Hellström C, Kammer P, Biström M, Ayoglu B, et al. Molecular
  mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with
  multiple sclerosis risk. Proc Natl Acad Sci U S A. 2019;116(34):16955-60. Epub 20190802.
  doi: 10.1073/pnas.1902623116. PubMed PMID: 31375628; PubMed Central PMCID:

679 PMCPMC6708327.

40. Sherbet GV. Molecular Approach to Targeted Therapy for Multiple Sclerosis. CNS Neurol

681 Disord Drug Targets. 2016;15(1):20-34. doi: 10.2174/1871527315666151110125840.

682 PubMed PMID: 26560895.

41. Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han MH. Molecular
signature of Epstein-Barr virus infection in MS brain lesions. Neurol Neuroimmunol
Neuroinflamm. 2018;5(4):e466. Epub 20180607. doi: 10.1212/nxi.00000000000466.

686 PubMed PMID: 29892607; PubMed Central PMCID: PMCPMC5994704.

42. Osipova-Goldberg HI, Turchanowa LV, Adler B, Pfeilschifter JM. H2O2 inhibits BCR-

688 dependent immediate early induction of EBV genes in Burkitt's lymphoma cells. Free Radic

689 Biol Med. 2009;47(8):1120-9. Epub 20090621. doi: 10.1016/j.freeradbiomed.2009.06.019.

690 PubMed PMID: 19540913.

43. Maple PAC, Gran B, Tanasescu R, Pritchard DI, Constantinescu CS. An Absence of

692 Epstein-Barr Virus Reactivation and Associations with Disease Activity in People with Multiple

693 Sclerosis Undergoing Therapeutic Hookworm Vaccination. Vaccines (Basel). 2020;8(3). Epub

694 20200828. doi: 10.3390/vaccines8030487. PubMed PMID: 32872342; PubMed Central

695 PMCID: PMCPMC7564729.

44. Torkildsen Ø, Nyland H, Myrmel H, Myhr KM. Epstein-Barr virus reactivation and multiple
sclerosis. Eur J Neurol. 2008;15(1):106-8. Epub 20071127. doi: 10.1111/j.14681331.2007.02009.x. PubMed PMID: 18042233.

45. Yea C, Tellier R, Chong P, Westmacott G, Marrie RA, Bar-Or A, Banwell B. Epstein-Barr
virus in oral shedding of children with multiple sclerosis. Neurology. 2013;81(16):1392-9.

701 Epub 20130906. doi: 10.1212/WNL.0b013e3182a841e4. PubMed PMID: 24014504; PubMed

702 Central PMCID: PMCPMC3806908.

- 46. Massa J, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Plasma titers of antibodies against
- 704 Epstein-Barr virus BZLF1 and risk of multiple sclerosis. Neuroepidemiology. 2007;28(4):214-5.
- 705 Epub 20070911. doi: 10.1159/000108113. PubMed PMID: 17851260.
- 706 47. Masuda S, Mori M, Arai K, Uzawa A, Muto M, Uchida T, et al. Epstein-Barr virus
- 707 persistence and reactivation in neuromyelitis optica. J Neurol Neurosurg Psychiatry.
- 708 2015;86(10):1137-42. Epub 20141128. doi: 10.1136/jnnp-2014-308095. PubMed PMID:
- 709 25433035.
- 48. Shi Z, Kong L, Wang R, Wang X, Wang Z, Luo W, et al. Cytomegalovirus and Epstein-
- 711 Barr virus infections in patients with neuromyelitis optica spectrum disorder. J Neurol. 2024.

712 Epub 20240724. doi: 10.1007/s00415-024-12571-2. PubMed PMID: 39046523.

49. Graves J, Grandhe S, Weinfurtner K, Krupp L, Belman A, Chitnis T, et al. Protective
environmental factors for neuromyelitis optica. Neurology. 2014;83(21):1923-9. Epub
20141022. doi: 10.1212/wnl.0000000000001001. PubMed PMID: 25339213; PubMed Central
PMCID: PMCPMC4248458.

717 50. Merelli E, Bedin R, Sola P, Barozzi P, Mancardi GL, Ficarra G, Franchini G. Human 718 herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis 719 patients, 1997;244(7):450-4. normal adults and children. J Neurol. doi: 720 10.1007/s004150050121. PubMed PMID: 9266465.

51. Nora-Krukle Z, Chapenko S, Logina I, Millers A, Platkajis A, Murovska M. Human
herpesvirus 6 and 7 reactivation and disease activity in multiple sclerosis. Medicina (Kaunas).

723 2011;47(10):527-31. PubMed PMID: 22186115.

724 52. Khalesi Z, Tamrchi V, Razizadeh MH, Letafati A, Moradi P, Habibi A, et al. Association 725 between human herpesviruses and multiple sclerosis: A systematic review and meta-analysis. 726 Microb Pathog. 2023;177:106031. Epub 20230210. doi: 10.1016/j.micpath.2023.106031. 727 PubMed PMID: 36775211. 728 53. Thakolwiboon S, Zhao-Fleming H, Karukote A, Pachariyanon P, Williams HG, Avila M. 729 Regional differences in the association of cytomegalovirus seropositivity and multiple 730 sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2020;45:102393. 731 Epub 20200712. doi: 10.1016/j.msard.2020.102393. PubMed PMID: 32683307. 732 54. Heerlein K, Jarius S, Jacobi C, Rohde S, Storch-Hagenlocher B, Wildemann B. 733 Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella 734 zoster infection. Sci. 2009;276(1-2):184-6. 20080920. J Neurol Epub doi:

735 10.1016/j.jns.2008.08.015. PubMed PMID: 18805556.

55. Sellner J, Hemmer B, M ü hlau M. The clinical spectrum and immunobiology of
parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun. 2010;34(4):371-9. Epub
20091022. doi: 10.1016/j.jaut.2009.09.013. PubMed PMID: 19853412.

56. Machado C, Amorim J, Rocha J, Pereira J, Lourenço E, Pinho J. Neuromyelitis optica
spectrum disorder and varicella-zoster infection. J Neurol Sci. 2015;358(1-2):520-1. Epub
20151004. doi: 10.1016/j.jns.2015.09.374. PubMed PMID: 26440423.

57. Wang L, Zhou L, ZhangBao J, Huang W, Tan H, Fan Y, et al. Causal associations
between prodromal infection and neuromyelitis optica spectrum disorder: A Mendelian
randomization study. Eur J Neurol. 2023;30(12):3819-27. Epub 20230816. doi:

745 10.1111/ene.16014. PubMed PMID: 37540821.

Exposure	Outcome	Method	Nsn	p pval				OR(95%CI)
Anti-CMV IgG seropositivity	MS	IVW	4	0.552	+			1.040 (0.915- 1.181)
CMV pp28 antibody levels	MS	IVW	9	0.533	÷			1.043 (0.914- 1.190)
CMV pp52 antibody levels	MS	IVW	12	0.937	÷			1.005 (0.897- 1.125)
CMV pp150 antibody levels	MS	IVW	7	0.157	÷.			1.127 (0.955- 1.329)
Anti-EBV IgG seropositivity	MS	IVW	6	0.103	÷			1.049 (0.990- 1.111)
EBV EA-D antibody levels	MS	IVW	3	0.001	-			0.544 (0.384- 0.773)
EBV EBNA-1 antibody levels	MS	IVW	7	4.772e-20			—	3.009 (2.377- 3.807)
EBV VCA p18 antibody levels	MS	IVW	8	1.059e-33			<b></b>	8.700 (6.128-12.351)
EBV ZEBRA antibody levels	MS	IVW	5	3.195e-08	-			0.592 (0.491- 0.713)
Anti-HHV 6 IgG seropositivity	MS	IVW	7	0.614	÷			1.016 (0.954- 1.083)
Anti-HHV 6 IE1A IgG seropositivity	MS	IVW	7	0.759	÷			0.987 (0.908- 1.073)
HHV6 IE1A antibody levels	MS	IVW	10	0.909	÷			0.990 (0.826- 1.186)
Anti-HHV6 IE1B IgG seropositivity	MS	IVW	7	0.272				0.958 (0.887- 1.034)
HHV6 IE1B antibody levels	MS	IVW	11	0.372	+			0.954 (0.859- 1.058)
HHV6 p101k antibody levels	MS	IVW	11	0.372	÷			0.954 (0.859- 1.058)
Anti-HHV7 IgG seropositivity	MS	IVW	8	0.541	+			0.988 (0.950- 1.028)
HHV7 U14 antibody levels	MS	IVW	2	2.187e-06			• •	3.359 (2.034- 5.546)
Anti-HSV 1 IgG seropositivity	MS	IVW	9	0.498	+			0.972 (0.895- 1.055)
HSV1 mgG-1 antibody levels	MS	IVW	14	0.569	÷			1.032 (0.925- 1.152)
Anti-HSV2 IgG seropositivity	MS	IVW	7	0.528	÷			1.034 (0.931- 1.149)
HSV2 mgG-1 antibody levels	MS	IVW	13	0.314				0.971 (0.917- 1.028)
VZV gE and gI antibody levels	MS	Wald ratio	1	0.001 I	•• •	1 1 2 3	. 4	0.106 (0.028- 0.406)

Fig 10MR estimate results of antibodies of five herpesviridae viru

Exposure	Outcome	Method	Nsnp	pval		OR(95%CI)
Anti-CMV IgG seropositivity	NMO	IVW	8	0.382		0.757 (0.405- 1.414)
CMV pp28 antibody levels	NMO	IVW	12	0.812	<b>—</b>	1.080 (0.574- 2.031)
CMV pp52 antibody levels	NMO	IVW	15	0.579	-	0.840 (0.453- 1.558)
CMV pp150 antibody levels	NMO	IVW	6	0.843		0.907 (0.345- 2.383)
Anti-EBV IgG seropositivity	NMO	IVW	9	0.368	+	1.108 (0.886- 1.385)
EBV EA-D antibody levels	NMO	IVW	4 <b>4</b>	.546e-05 <b>•</b>	-	0.043 (0.010- 0.196)
EBV EBNA-1 antibody levels	NMO	IVW	21	0.692	+	0.889 (0.498- 1.589)
EBV VCA p18 antibody levels	NMO	IVW	19	0.016		0.389 (0.181- 0.840)
EBV ZEBRA antibody levels	NMO	IVW	19 <b>7</b> .	.587e-16 •		0.079 (0.043- 0.147)
Anti-HHV 6 IgG seropositivity	NMO	IVW	10	0.840	÷	0.975 (0.761- 1.248)
Anti-HHV 6 IE1A IgG seropositivity	NMO	IVW	14	0.026	+	0.628 (0.416- 0.947)
HHV6 IE1A antibody levels	NMO	IVW	20	0.006	-	0.281 (0.113- 0.698)
Anti-HHV6 IE1B IgG seropositivity	NMO	IVW	14	0.614	+	0.920 (0.665- 1.273)
HHV6 IE1B antibody levels	NMO	IVW	20	0.385		0.710 (0.327- 1.539)
HHV6 p101k antibody levels	NMO	IVW	9	0.588	+	1.129 (0.728- 1.753)
Anti-HHV7 IgG seropositivity	NMO	IVW	15	0.700	+	1.079 (0.733- 1.588)
HHV7 U14 antibody levels	NMO	IVW	5 <b>2</b>	.285e-04		→ 10.641 (3.025-37.429)
Anti-HSV 1 IgG seropositivity	NMO	IVW	11	0.752	+	0.924 (0.566- 1.508)
HSV1 mgG-1 antibody levels	NMO	IVW	22	0.019	-	0.535 (0.317- 0.902)
Anti-HSV2 IgG seropositivity	NMO	IVW	10	0.739	+	1.056 (0.766- 1.455)
HSV2 mgG-1 antibody levels	NMO	IVW	16	0.625	+	1.074 (0.806- 1.432)
VZV gE and gI antibody levels	NMO	IVW	14 8	<b>3.727е-23</b> Г 0	1 2	→ 17.220 (9.760-30.380) 3 4

Fig 2 MR estimate results of antibodies of five herpesviridae viru

Exposure	Outcome	Method	Nsnp	pval		OR(95%CI)
Anti-CMV IgG seropositivity	MG	IVW	13	0.880	+	0.989 (0.860-1.138)
CMV pp28 antibody levels	MG	IVW	18	0.369	+	1.085 (0.908-1.296)
CMV pp52 antibody levels	MG	IVW	24	0.485	÷	1.060 (0.900-1.250)
CMV pp150 antibody levels	MG	IVW	8	0.938	÷	1.013 (0.735-1.396)
Anti-EBV IgG seropositivity	MG	IVW	13	0.057	+	1.063 (0.998-1.131)
EBV EA-D antibody levels	MG	IVW	3	0.004 -	-	0.414 (0.229-0.751)
EBV EBNA-1 antibody levels	MG	IVW	24	0.058	-	1.172 (0.994-1.382)
EBV VCA p18 antibody levels	MG	IVW	10	0.457	÷	1.105 (0.850-1.437)
EBV ZEBRA antibody levels	MG	IVW	19	0.366	+	1.093 (0.901-1.326)
Anti-HHV 6 IgG seropositivity	MG	IVW	13	0.497	+	1.035 (0.937-1.144)
Anti-HHV 6 E1A IgG seropositivity	MG	IVW	13	0.096	+	1.097 (0.984-1.223)
HHV6 IE1A antibody levels	MG	IVW	16	0.103		1.205 (0.963-1.509)
Anti-HHV6 IE1B IgG seropositivity	MG	IVW	18	0.677	÷	0.980 (0.893-1.076)
HHV6 IE1B antibody levels	MG	IVW	28	0.408	4	0.923 (0.765-1.115)
HPV6 p101k antibody levels	MG	IVW	20	0.803	÷	1.013 (0.917-1.118)
Anti-HHV7 IgG seropositivity	MG	IVW	18	0.847	÷	1.005 (0.955-1.058)
HHV7 U14 antibody levels	MG	IVW	8	0.834	- <b>i</b>	1.043 (0.706-1.539)
Anti-HSV 1 IgG seropositivity	MG	IVW	15	0.459	+	1.050 (0.923-1.194)
HSV1 mgG-1 antibody levels	MG	IVW	27	0.839	+	1.017 (0.866-1.194)
Anti-HSV2 IgG seropositivity	MG	IVW	17	0.124		1.067 (0.982-1.160)
HSV2 mgG-1 antibody levels	MG	IVW	21	0.927	÷	0.996 (0.914-1.085)
VZV gE and gI antibody levels	MG	IVW	12 5	5. <b>897e-13</b>		2.542 (1.972-3.277) 4

Fig 3 MR estimate results of antibodies of five herpesviridae viru

Exposure	Outcome	Method	Nsnp	pval		OR(95%CI)
Anti-CMV IgG seropositivity	GBS	IVW	13	0.083	+	1.266 (0.970-1.653)
CMV pp28 antibody levels	GBS	IVW	19	0.469		1.129 (0.814-1.566)
CMV pp52 antibody levels	GBS	IVW	21	0.335	+	1.157 (0.860-1.557)
CMV pp150 antibody levels	GBS	IVW	8	0.713		1.103 (0.655-1.856)
Anti-EBV IgG seropositivity	GBS	IVW	12	0.442	+	0.952 (0.840-1.079)
EBV EA-D antibody levels	GBS	IVW	10	0.792	<u>+</u>	1.054 (0.715-1.553)
EBV EBNA-1 antibody levels	GBS	IVW	36	0.079		0.849 (0.708-1.019)
EBV VCA p18 antibody levels	GBS	IVW	17	0.003		0.643 (0.479-0.863)
EBV ZEBRA antibody levels	GBS	IVW	25	0.967		1.005 (0.782-1.292)
Anti-HHV 6 IgG seropositivity	GBS	IVW	13	0.539	+	0.961 (0.846-1.092)
Anti-HHV 6 IE1A IgG seropositivity	GBS	IVW	22	0.622	+	0.959 (0.813-1.132)
HHV6 IE1A antibody levels	GBS	IVW	24	0.861		1.029 (0.748-1.416)
Anti-HHV6 IE1B IgG seropositivity	GBS	IVW	19	0.872	+	1.015 (0.843-1.222)
HHV6 IE1B antibody levels	GBS	IVW	29	0.794	-	0.959 (0.698-1.317)
HHV6 p101k antibody levels	GBS	IVW	21	0.766	+	0.975 (0.824-1.153)
Anti-HHV7 IgG seropositivity	GBS	IVW	19	0.204	÷	1.049 (0.974-1.130)
HHV7 U14 antibody levels	GBS	IVW	9	0.068		0.629 (0.383-1.035)
Anti-HSV 1 IgG seropositivity	GBS	IVW	16	0.308		0.896 (0.725-1.107)
HSV1 mgG-1 antibody levels	GBS	IVW	31	0.312	+	1.157 (0.872-1.535)
Anti-HSV2 IgG seropositivity	GBS	IVW	16	0.533		1.063 (0.876-1.290)
HSV2 mgG-1 antibody levels	GBS	IVW	21	0.662	+	1.034 (0.891-1.199)
VZV gE and gI antibody levels	GBS	IVW	19	0.878		0.977 (0.723–1.319) 1 2

Fig 4 MR estimate results of antibodies of five herpesviridae viru

Exposure	Outcome	Method	Nsnp	pval		OR(95%CI)
Anti-CMV IgG seropositivity	CIDP	IVW	14	0.713	+	1.042 (0.837-1.298)
CMV pp28 antibody levels	CIDP	IVW	20	0.492		0.912 (0.702-1.186)
CMV pp52 antibody levels	CIDP	IVW	24	0.623		1.067 (0.823-1.384)
CMV pp150 antibody levels	CIDP	IVW	8	0.930	_	0.974 (0.541-1.753)
Anti-EBV IgG seropositivity	CIDP	IVW	14	0.576	+	0.974 (0.886-1.069)
EBV EA-D antibody levels	CIDP	IVW	14	0.867		1.026 (0.762-1.381)
EBV EBNA-1 antibody levels	CIDP	IVW	44	0.148		0.914 (0.809-1.033)
EBV VCA p18 antibody levels	CIDP	IVW	20	0.165	-+	0.850 (0.675-1.069)
EBV ZEBRA antibody levels	CIDP	IVW	32	0.724	+	0.972 (0.832-1.136)
Anti-HHV 6 IgG seropositivity	CIDP	IVW	13	0.174		0.921 (0.818-1.037)
Anti-HHV 6 IE1A IgG seropositivity	CIDP	IVW	23	0.447	+	0.943 (0.812-1.096)
HHV6 IE1A antibody levels	CIDP	IVW	26	0.032		1.335 (1.025-1.738)
Anti-HHV6 IE1B IgG seropositivity	CIDP	IVW	22	0.101		0.895 (0.784-1.022)
HHV6 IE1B antibody levels	CIDP	IVW	30	0.342		0.885 (0.689-1.138)
HPV6 p101k antibody levels	CIDP	IVW	21	0.382		0.930 (0.791-1.094)
Anti-HHV7 IgG seropositivity	CIDP	IVW	17	0.509	÷	1.027 (0.949-1.111)
HHV7 U14 antibody levels	CIDP	IVW	9	0.767		1.071 (0.681-1.685)
Anti-HSV 1 IgG seropositivity	CIDP	IVW	14	0.422		1.087 (0.886-1.334)
HSV1 mgG-1 antibody levels	CIDP	IVW	30	0.401		0.877 (0.646-1.191)
Anti-HSV2 IgG seropositivity	CIDP	IVW	15	0.883	+	0.989 (0.856-1.143)
HSV2 mgG-1 antibody levels	CIDP	IVW	22	0.652	+	0.964 (0.820-1.132)
VZV gE and gI antibody levels	CIDP	IVW	26	0.869		1.016 (0.843–1.224) 1 2

Fig 5 MR estimate results of antibodies of five herpesviridae viru